Publication | Closed Access

Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payerʼs Perspective

ThrombosisPulmonary EmbolismRivaroxaban Versus EnoxaparinVenous DiseaseVenous ThrombosisHealth EconomicsMedicinePatient SafetyVascular SurgeryOutcomes ResearchSurgeryCost EffectivenessUs Payerʼs PerspectiveAnticoagulantAnesthesiology